ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.
ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate, it was unveiled in a Jan. 14, 2020 press release.
Under the terms of the agreement, ProBioGen will conduct cell line development of a γδ T-cell engaging bispecific antibody format using its CHO.RIGHT expression platform. The γδ T-cell engaging bispecific antibodies for the treatment of cancer will be developed by Lava Therapeutics.
“We like to get our hands on novel protein formats,” said Dr. Wieland Wolf, ProBioGen’s CEO, in the press release. “And we are very much looking forward conducting this project together with Lava Therapeutics.”
“Solving the manufacturing requirements early in drug development is a key element to enabling the future success of a program,” added Steve Hurly, CEO at Lava Therapeutics, in the press release. “With ProBioGen, we found a scientific-driven partner with a proven development platform and a dedicated analytical panel for challenging bispecific antibody formats.”
Source: ProBioGen
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.